Kimberly-Clark de Mexico SAB de CV AI Stock Analysis
Want to see KCDMY full AI Analyst Report?
Kimberly-Clark de Mexico SAB de CV (KCDMY) AI Stock Analysis
Kimberly-Clark de Mexico SAB de CV
(Other OTC:KCDMY)
The overall score of 58 reflects a company with strong operational momentum and cash generation that is significantly overshadowed by a highly leveraged balance sheet and bearish market sentiment. The primary risk is the aggressive debt level, which makes the company vulnerable in a downturn. While the valuation is reasonable and the dividend yield is attractive, the technical trend is negative and the near-term demand outlook is weak. The company's ability to navigate cost pressures and sustain its cash flow to deleverage will be critical.
Kimberly-Clark de Mexico SAB de CV (KCDMY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.29B
- Dividend Yield
- 5.64%
- Average Volume (3M)
- 44.50K
- Price to Earnings (P/E)
- 14.8
- Beta (1Y)
- 0.12
- Revenue Growth
- 13.74%
- EPS Growth
- 24.96%
- Country
- US
- Employees
- 9,400
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
Kimberly-Clark de Mexico SAB de CV Business Overview & Revenue Model
Company Description
Kimberly-Clark de México, S. A. B. de C. V., through its subsidiaries, manufactures and distributes a wide array of disposable consumer goods for everyday use across Mexico. The company's diverse product offering spans several categories: infant care...
How the Company Makes Money
Kimberly-Clark de México makes money primarily by manufacturing and selling branded hygiene and tissue products in Mexico. Revenue is generated through (1) consumer retail sales, where products such as diapers, feminine care, adult care, and tissue p...
Kimberly-Clark de Mexico SAB de CV Earnings Call Summary
The call was broadly positive, supported by higher year-to-date EBITDA and EPS, margin expansion, substantial cost savings, a strong balance sheet, continued Consumer Products growth, and encouraging private label, pet food, and innovation initiatives. However, the quarter also reflected flat total sales, weak consumer demand, declines in Away from Home and exports, higher SG&A and financing costs, and persistent cost pressures. Management remained confident in execution and potential 2027 improvement, but acknowledged that the near-term environment remains challenging.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects weak consumer demand to stretch through the end of the year, with cost pressures continuing through the fourth quarter, maybe at slightly lower levels, and expects a slightly better fourth quarter for Away from Home and a much better 2027. Going into 2027, it expects steady improvements in demand, improving growth rates and increased, although still moderate, domestic spending; Consumer Products could get back to growing at the rate seen in the first half of the year, or mid-single digit, if domestic consumption picks up. Private label will likely a little bit more than double in size this year, with the same thing expected to happen next year, while CapEx is expected to remain around between MXN 100 million and MXN 120 million for the year in 2027 and following years. The company remains comfortable staying within its 25% to 27% margin long-term range, expects its KCM plus initiatives and cost reduction program to accelerate, and expects a resolution on Kenvue Mexico by the fourth quarter.
Kimberly-Clark de Mexico SAB de CV Financial Statement Overview
Summary
Financial performance is a tale of two stories. Operational execution is strong, with robust TTM revenue growth of 20.1%, expanding margins, and excellent cash flow conversion (85.7% of net income). However, the balance sheet is a critical weakness, with a debt-to-equity ratio spiking to 7.45x, indicating an aggressive and risky capital structure. The overall score reflects this tension between strong profitability and high financial leverage.
Income Statement
78PositiveBalance Sheet
35NegativeCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.30B | 51.94B | 54.78B | 53.31B | 51.06B | 46.89B |
| Gross Profit | 23.00B | 20.19B | 22.38B | 20.70B | 16.77B | 15.79B |
| EBITDA | 15.36B | 13.97B | 16.09B | 15.23B | 11.58B | 10.79B |
| Net Income | 7.94B | 7.11B | 7.83B | 7.01B | 4.94B | 4.49B |
Balance Sheet | ||||||
| Total Assets | 56.45B | 45.71B | 52.11B | 53.92B | 53.54B | 48.78B |
| Cash, Cash Equivalents and Short-Term Investments | 20.23B | 9.68B | 15.58B | 16.86B | 16.92B | 12.27B |
| Total Debt | 30.03B | 21.36B | 28.10B | 29.72B | 34.15B | 29.83B |
| Total Liabilities | 51.01B | 38.46B | 44.70B | 47.00B | 48.51B | 43.06B |
| Stockholders Equity | 5.37B | 7.25B | 7.41B | 6.92B | 5.03B | 5.72B |
Cash Flow | ||||||
| Free Cash Flow | 9.83B | 6.09B | 8.10B | 11.08B | 6.18B | 4.65B |
| Operating Cash Flow | 11.35B | 7.80B | 10.60B | 12.76B | 8.32B | 6.80B |
| Investing Cash Flow | -1.28B | -1.72B | -1.30B | -311.39M | -2.15B | -2.14B |
| Financing Cash Flow | -287.88M | -11.02B | -13.50B | -9.83B | -1.32B | -11.07B |
Kimberly-Clark de Mexico SAB de CV Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KCDMY, the sentiment is Neutral. The current price of 10.56 is above the 20-day moving average (MA) of 10.29, below the 50-day MA of 10.63, and below the 200-day MA of 11.06, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 53.81 is Neutral, neither overbought nor oversold. The STOCH value of 83.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KCDMY.
Kimberly-Clark de Mexico SAB de CV Peers Comparison
Overall Rating
CHD78Outperform
PG72Outperform
CLX64Neutral
UL64Neutral- KCDMY58Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CHD | 78Outperform | $26.44B | 34.27 | 18.21% | 1.10% | 1.70% | 2.07% |
| PG | 72Outperform | $388.62B | 24.95 | 29.55% | 2.57% | 3.52% | -3.74% |
| CLX | 64Neutral | $12.95B | 19.42 | -1920.57% | 4.60% | 6.28% | -13.15% |
| UL | 64Neutral | $140.19B | 13.88 | 58.26% | 3.26% | -17.45% | 8.84% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| KCDMY | 58Neutral | $6.12B | 14.78 | 165.92% | 5.64% | 13.74% | 24.96% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KCDMY | Kimberly-Clark de Mexico SAB de CV (ADR) | 10.56 | 0.94 | 9.73% | |
| CHD | Church & Dwight Company | 111.73 | 29.48 | 35.85% | |
| CLX | Clorox Company | 108.20 | 11.89 | 12.34% | |
| PG | Procter & Gamble Company | 168.03 | 26.32 | 18.57% | |
| UL | Unilever plc | 66.03 | 4.19 | 6.77% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026